These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17652007)

  • 1. Pediatric oncology.
    Kurmasheva RT; Houghton PJ
    Curr Opin Chem Biol; 2007 Aug; 11(4):424-32. PubMed ID: 17652007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-IR: potential role in antitumor agents.
    Guerreiro AS; Boller D; Doepfner KT; Arcaro A
    Drug News Perspect; 2006 Jun; 19(5):261-72. PubMed ID: 16941048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
    Choy H; Milas L
    J Natl Cancer Inst; 2003 Oct; 95(19):1440-52. PubMed ID: 14519750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying novel therapeutic agents using xenograft models of pediatric cancer.
    Kurmasheva RT; Houghton PJ
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):221-32. PubMed ID: 27193096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules.
    Ito F
    Biol Pharm Bull; 2011; 34(12):1773. PubMed ID: 22130228
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic targeting of apoptotic pathways in cancer.
    Meiler J; Schuler M
    Curr Drug Targets; 2006 Oct; 7(10):1361-9. PubMed ID: 17073598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.
    Hixon ML; Paccagnella L; Millham R; Perez-Olle R; Gualberto A
    Rev Recent Clin Trials; 2010 Sep; 5(3):189-208. PubMed ID: 20533896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cracking the mild, difficult and fiendish codes within and downstream of the EGFR to link diagnostics and therapeutics.
    Waterfield M
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):1-6. PubMed ID: 17212578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Opportunities for Childhood Cancer Drug Development.
    Houghton PJ; Kurmasheva RT
    Pharmacol Rev; 2019 Oct; 71(4):671-697. PubMed ID: 31558580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on the discovery of NOTCH2-specific inhibitors.
    Dobranowski P; Ban F; Contreras-Sanz A; Cherkasov A; Black PC
    Chem Biol Drug Des; 2018 Mar; 91(3):691-706. PubMed ID: 29078041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
    Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
    Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving paradigms for new agent development in pediatric oncology.
    Flynn A; Fox E
    Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.